Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Neratinib + Temozolomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Neratinib||Nerlynx||HKI-272|PB272||HER2 Inhibitor 26||Nerlynx (neratinib) inhibits the ERBB2 (HER2) receptor as well as EGFR, resulting in decreased proliferation of HER2 and EGFR expressing tumor cells (PMID: 15173008). Nerlynx (neratinib) is FDA approved for use in patients with early stage ERBB2 (HER2)-positive breast cancer following Herceptin (trastuzumab)-based therapy, and in combination with Xeloda (capecitabine) in patients with advanced/metastatic ERBB2 (HER2)-positive breast cancer who have received two or more anti-ERBB2 (HER2) regimens (FDA.gov).|
|Temozolomide||Temodar||Methazolastone||Chemotherapy - Alkylating 15||Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02977780||Phase II||CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide||INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)||Recruiting||USA||0|